1 2	Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation
3 4 5	Amneet Sandhu, MD, MSc ^{1,2} ; Lisa A. Kaltenbach, MS ⁴ ; Karen Chiswell, PhD ⁴ ; Vijay Shimoga, BS ⁶ ; Carmel Ashur, MD ² ; Abby Pribish, MD ² ; Gregg C. Fonarow, MD ⁵ ; Jonathan P. Piccini Sr, MD ^{3,4} ; P. Michael Ho, MD, PhD ^{1,2} ; Paul D. Varosy, MD ^{1,2} ; Paul L. Hess, MD, MHS ^{1,2}
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 	

45 ABSTRACT

46 Introduction:

47 Among patients hospitalized for atrial fibrillation (AF), the frequency of off-label direct oral

- 48 anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends
- 49 in contemporary clinical practice are unknown.
- 50

51 Methods:

52 Using the Get With The Guidelines[®] Atrial Fibrillation (GWTG-AF) registry, patients admitted

- from January 1st, 2014 to March 31st, 2020, and discharged on DOAC therapy were stratified
- 54 according to receipt of underdosing, overdosing, or recommended dosing. Factors associated
- 55 with off-label dosing were identified using logistic regression. Hospital-level variation and
- 56 temporal trends were assessed.
- 57

58 Results:

- 59 Of 22,470 patients prescribed a DOAC at discharge from hospitalization for AF (66% apixaban,
- 60 29% rivaroxaban, 5% dabigatran), underdosing occurred among 2006 (8.9%), overdosing among
- 511 (2.3%), and recommended dosing among 19953 (88.8%). Patient-related factors associated
- 62 with off-label DOAC use included age (underdosing: OR 1.06 per 1-year increase [95% CI 1.06-
- 63 1.07] and overdosing: OR 1.07 per 1-year increase [1.06-1.09]), dialysis dependence
- 64 (underdosing: OR 5.50 [3.76-8.05] and overdosing: OR 5.47 [2.74-10.88]), female sex
- 65 (overdosing: OR 0.79 [0.63-0.99]) and weight (overdosing: OR 0.96 per 1-Kg increase [0.95-
- 66 1.00]). Across hospitals, the adjusted median odds ratio for off-label DOAC use was 1.45 [95%
- 67 CI 1.34-1.65] (underdosing: 1.52 [1.39-1.76] and overdosing: 1.32 [1.20-1.84]), indicating
- 68 significant hospital-level variation. Hospital characteristics associated with underdosing
- 69 included West vs. Northeast location (OR: 1.55 [1.04-2.31]), rural vs. urban setting (OR: 0.48
- 70 [0.28-0.83]), and number of beds (<200 vs. 500+, OR: 1.95 [1.29-2.95]). Recommended dosing
- significantly increased over time (81.9% in 2014 to 90.9% in 2020, p<0.0001 for trend) with a
- corresponding decline in underdosing (14.4% in 2014 to 6.6% in 2020, p<0.0001 for trend) and
- 73 overdosing (3.8% in 2014 to 2.5% in 2020, p=0.001 for trend).
- 74

75 **Conclusion:**

76 One of 10 patients hospitalized for atrial fibrillation is discharged on off-label dosing of DOAC

- 77 with significant variation across hospitals. While the proportion of patients receiving
- 78 recommended dosing has significantly improved over time, opportunities to improve DOAC
- 79 dosing persist.
- 80
- 81 82
- 83
- 84
- 85
- 86
- 87
- 88

89 INTRODUCTION

90 Appropriately dosed direct oral anticoagulants (DOACs) reduce the risk of stroke and systemic embolism among select patients with atrial fibrillation (AF).¹⁻³ The Food and Drug 91 Administration (FDA) specified dosing derived from pivotal phase III trials¹⁻³ based on factors 92 93 inclusive of age, weight, kidney function, and concomitant medication use. Unfortunately, use 94 of DOACs at doses not studied in the pivotal trials or recommended in FDA-labeling has been significant, affecting up to 12-20% of patients.⁴⁻⁷ Off-label DOAC dosing for AF has been 95 observed in the outpatient setting and is associated with increased risk of cardiovascular 96 hospitalization and all-cause mortality.^{5,6} Meta-analyses have also shown an increased bleeding 97 risk with DOAC overdosing and higher stroke risk with DOAC underdosing.⁸ 98

99 The degree to which off-label DOAC dosing occurs in patients hospitalized for AF is 100 unknown. Hospitalizations often are associated with significant changes in health critical to 101 prescription of an optimal DOAC dose, including weight, kidney function, and concurrent 102 medication use. Temporal trends in off-label DOAC use and how use of these agents varies 103 between hospitals is not known. Accordingly, using data from the Get With The Guidelines[®]-104 Atrial Fibrillation (GWTG-AFIB) registry, we sought to characterize (1) off-label DOAC dosing 105 rates at discharge among patients requiring hospitalization for AF, (2) patient- and facility-level 106 factors associated with off-label DOAC dosing and (3) temporal changes in the proportion of 107 patients treated with off-label DOAC dosing.

108

109 METHODS

110 Data Source

111 The data used were collected by the American Heart Association's Get With The 112 Guidelines®-AFib registry. GWTG-AFIB registry was launched in 2013 as a prospective, national, 113 observational initiative tracking hospital encounters for atrial fibrillation. The program and data elements of the GWTG-AFIB registry have been previously described.⁹ IQVIA (Parsippany, New 114 Jersey) serves as the data collection and coordination center. A key objective of the GWTG 115 116 program is to highlight national and institutional-level opportunities for quality improvement. 117 Each participating hospital received either human research approval to enroll cases without individual patient consent under the common rule, or a waiver of authorization and exemption 118 119 from subsequent review by their institutional review board. The Duke Clinical Research Institute 120 (Durham, NC) serves as the data analysis center and has an agreement to analyze the aggregate 121 deidentified data for research purposes. The Institutional Review Board at Duke University 122 Health approved this study. Participating sites were required to adhere to local regulatory and 123 privacy procedures and obtain Institutional Review Board approval if needed. Institutional 124 review board approval was granted to analyze limited data for research purposes. 125

126 <u>Study Population</u>

127 The study population included patients who required hospital care for management of 128 atrial fibrillation or atrial flutter and were discharged on a DOAC (apixaban, rivaroxaban or 129 dabigatran between January 1st, 2014 and March 31st, 2020). Patient records that were (1) 130 missing key demographic variables or medical history including age, sex, weight or history of 131 atrial fibrillation, (2) missing discharge anticoagulant, dose, or frequency, (3) missing serum 132 creatinine data at the time of discharge, (4) contraindications to DOAC or anticoagulant use or

(5) document special circumstances (transition to comfort care or discharged against medical
 advice) or had missing destination after discharge were excluded (Supplemental Figure 1).

135

136 <u>Study Definition</u>

137 The designation of "off-label" was defined as deviation from dosing specified by FDA package inserts and used in the seminal DOAC trials.¹⁻³ They are based on age, weight, kidney 138 function at discharge, and comorbid conditions such as need for dialysis (Supplemental Table 139 1).¹⁰⁻¹² Recommended dosing of dabigatran varies by creatinine clearance (CrCl >30 ml/min = 140 141 150mg orally twice daily and CrCl 15-30 ml/min = 75 mg orally twice daily). For apixaban, recommended dosing is 5 mg twice daily. In the presence of any 2 of 3 factors comprised of 142 143 age >80 years, weight <60 kg and a serum creatinine of >1.5 mg/dL, recommended dosing is 144 2.5mg orally twice daily. Recommended rivaroxaban dosing varies by creatinine clearance (>50 145 ml/min = 20mg orally once daily, 15-50 ml/min = 15mg orally once daily, and <15 ml/min = not 146 recommended).

147

148 Statistical Analysis

149 Patient characteristics were stratified by discharge DOAC dose characterized as 150 underdosing, recommended dosing, or overdosing. Categorical variables were recorded as 151 counts (percentages) and continuous variables reported as a median (Q1, Q3). Assessments of between-group differences were performed using Pearson χ^2 or Fisher's exact test as 152 appropriate for the former and Kruskal-Wallis tests for the latter. In sensitivity analyses, rates 153 154 of off-label dosing were assessed among patients with newly diagnosed AF, those were admitted on DOAC and discharged with a different prescription, and according to weight (≤ 60 155 156 kg, 60-120 kg, >120 kg or body mass index >40 Kg/m2).

157 To assess patient- and hospital-level factors associated with off-label dosing, overdosing 158 was compared with recommended dosing and underdosing was compared with recommended 159 dosing. In each case, a logistic regression model with stepwise selection was fitted using a 160 significance of 0.10 to enter and remain in the model. Candidate variables were selected based on prior literature^{5,6} and clinical judgment which included demographics (age, sex, race and 161 ethnicity), conditions affecting prior health (such as coronary artery disease, prior stroke or TIA, 162 163 diabetes, hypertension, COPD, OSA, prior myocardial infarction, prior PCI, thyroid disease, prior 164 hemorrhage, PVD, dialysis, liver disease, heart failure), other patient characteristics (such as left ventricular ejection fraction and history of other arrhythmias, smoking, insurance status), and 165 166 hospital characteristics (region, academic, bedsize, rural). After variable selection, a random 167 intercept for hospital to account for within hospital clustering was added. We assessed whether 168 patient- or hospital-level factors play a larger role in inappropriate dosing using reference effect measures¹³, which compare patients in clusters at specified percentiles of the random effect of 169 170 the distribution to patients with the same values for all measured covariates in a reference 171 cluster. To make comparisons of site variability, variables were scaled such that odds ratios are 172 comparable across variables. Whereas binary variables were dichotomized as in their original 173 form, continuous variables were divided by 2*standard deviation (SD). 174 To characterize variation across hospitals, the percentage of patients with off-label

dosing out of the total number of patients eligible for DOAC dosing was calculated for each
 hospital. Hospitals with <30 admissions in the study population were excluded. Hospital-level

variation use was then graphically displayed using a caterpillar plot. To account for variation in 177 178 the number of patients per site, a hierarchical logistic regression model with random intercepts 179 for site was fitted. The model was then used to test whether variance components for site 180 were greater than zero and to calculate the median odds ratio (MOR) between sites. The MOR can be interpreted as the median increase in odds of off-label dosing when an individual moves 181 182 from a lower to a higher-risk hospital. It provides an estimate of the effect size of the hospital variation on the outcome of off-label DOAC dosing. A MOR >1.2 represents significant clinical 183 variation.¹⁴ 184

185 To describe temporal trends in percentage off-label DOAC dosing, the percentage of patients with off-label dosing was calculated by calendar guarter beginning in 2014. Trends in 186 187 percentage of recommended dosing, underdosing, and overdosing over time was graphically 188 displayed. To assess temporal trend significance, unadjusted and adjusted logistic regression 189 models with random intercepts for site were fitted for overdosing versus recommended dosing 190 and underdosing versus recommended dosing. The final clinical variables of the models 191 described as well as random intercepts for site and time in quarters were included. The effect 192 of quarterly trends of off-label DOAC dosing was estimated using odds ratios (95% confidence 193 intervals). 194

195 **RESULTS**

Among 22,470 patients discharged after a hospital encounter for AF, 2006 (8.9%)
received a DOAC that was lower than the recommended dose, 19953 (88.8%) received a DOAC
at recommended dosing, and 511 (2.3%) received a DOAC that was higher than the
recommended dose. Figure 1 displays underdosing, overdosing, and recommended dosing by
DOAC type and overall.

201 **Table 1** displays patient-level data for the overall cohort and stratified by underdosed, 202 recommended dosing and overdosed. In the overall population, the mean age was 70.1 +/- 12.1 years old, 48.1% were female, and the mean body mass index was $31.2 + 7.9 \text{ Kg/m}^2$. The 203 204 mean CHADS2Vasc score was 3.76 +/- 1.75, 42.0% had paroxysmal AF and 37.6% had chronic 205 kidney disease resulting in an eGFR <60 ml/min while 0.7% were on hemodialysis. Relative to 206 those discharged on DOAC dosing consistent with FDA labeling, patients who received 207 underdosed DOACs were older (77.0 +/- 11.2 years vs. 69.1 +/- 11.9), more commonly on 208 dialysis (2.7% vs. 0.5%), more frequently had a prior hemorrhage (4.7% vs. 2.6%), and more 209 frequently received care at hospitals located in non-rural settings (4.8% vs. 4.4%) or with less 210 than 500 beds (43.4% vs. 33.8%). Relative to FDA-labeled use of DOACs on discharge, those 211 who received overdosed DOACs were older (80.6 +/- 7.8 years vs 69.1 +/- 11.9), more 212 frequently women (66.3% vs. 46.6%), usually had a lower body mass index (25.1 +/- 5.8 vs. 31.5 213 +/- 5.8), and more frequently were on dialysis (2.4% vs. 0.5%). In sensitivity analyses of rates of 214 lower than recommended dose, recommended, and higher than recommended dose by new AF

- 215 diagnosis, change in DOAC type (ie. from apixaban to rivaroxaban) during hospitalization or
- 216 patient weight, findings were comparable to the primary analysis.

Figures 2 displays factors associated with overdosing and underdosing relative to
 recommended dosing as well as measures of variation across hospitals. In multivariable
 modeling, higher rates of underdosing were associated with patient-level factors such as older
 age, dialysis dependence, and prior hemorrhage and hospital-level factors such as Western and

urban location as well as servicing relatively few beds. Across hospitals, the reference effect
measure for random site variation of receipt of underdosed DOAC at discharge (90th percentile
in comparison to median hospital) was OR 1.75 (95% CI 1.54-2.00). Higher rates of overdosing
were associated with patient-level factors such as older age and dialysis dependence. Hospitallevel factors were not significantly contributory. Across hospitals, the reference effect measure
for random site variation of receipt of an overdosed DOAC at discharge (90th percentile in

comparison to median hospital) was OR 1.46 (95% CI 1.29-1.65).

228 Across participating sites, the median observed percent of off-label DOAC use was 229 10.9% (IQR 6.8 – 15.9%). Figure 3 displays hospital-level variation in the rate of off-label DOAC 230 use in addition to hospital-level variation in rates of underdosing and overdosing. The overall 231 adjusted MOR for off-label DOAC use across hospitals was 1.45 (95% CI 1.34-1.65) [REM or 232 random effects model range 0.47-2.14], indicating significant variation across sites. The 233 adjusted MOR for underdosing was 1.52 (95% CI 1.39-1.76) [REM range 0.42-2.36] and 234 overdosing 1.32 (1.20-1.84) [REM range 0.56-1.78]. Table 2 shows that in random effects 235 models, while patient factors contributed more to variability than facility-level factors, facility-236 level factors were nonetheless significantly contributory to both underdosing and overdosing. 237 Figure 4 shows temporal trends in the rates of recommended dosing, underdosing, and 238 overdosing of DOACs. There was a significant increase in recommended dosing from 81.9% in 239 2014 to 90.9% in 2020, p <0.0001 for trend. There was a significant decline in those receiving 240 underdosing (14.4% in 2014 to 6.6% in 2020, p<0.0001 for trend) and overdosing (3.8% in 2014 to 2.5% in 2020, p=0.001 for trend) dosing over the study period. 241

242243 **DISCUSSION**

244 In this nationwide analysis of more than 22,000 patients hospitalized for care of atrial 245 fibrillation and discharged on DOACs, there are three key findings. First, 1 of 10 patients 246 hospitalized for AF receive under or overdosed DOACs. Second, significant hospital-level 247 variation exists with regards to use of off-label DOAC dose, with the greatest opportunity for future improvement in hospitals that are Western, urban, or of comparatively small size. Third, 248 249 over the study period, rates of recommended DOAC dosing increased and off-label use 250 decreased. These results characterize favorable national trends in DOAC use while identifying 251 continued opportunities to improve safe and appropriate DOAC dosing at hospital discharge. 252 Prior work has analyzed rates of off-label DOAC dose in ambulatory outpatients (9.4% 253 are underdosed, 3.4% overdosed and 87% per recommendation) correlating adverse cardiovascular or bleeding events in those who received off-label dosing.⁶ Our work extends 254 that of prior analyses by focusing on patients hospitalized with AF and reveals rates of off-label 255 use (8.9% underdosed, 2.3% overdosed) similar to that seen among outpatients.^{6,15} 256 257 Encouragingly, rates of recommended dosing remain relatively high and are comparable to prior, smaller analyses in patients with atrial fibrillation warranting long-term anticoagulation.¹⁶ 258 259 Consistent with prior, smaller studies, we found that several patient characteristics are more common in those treated with an off-label dose, including older age, weight, and dialysis 260 dependence.^{6,17} The DOACs studied (apixaban, rivaroxaban and dabigatran) account for the 261 majority of DOAC use in the United States.^{18,19} Broadly, these data provide opportunities to 262 address this quality gap, focusing on patient profiles at-risk for off-label DOACs dose, risk of 263 264 over or underdosing based on type of DOAC utilized. These profiles may prove useful both at

the time of hospital discharge as well as during post-hospitalization follow-up clinicalencounters.

267 Significant hospital-level variation of off-label DOACs use exists after accounting for 268 measured variables. This finding suggests unmeasured aspects of site-level care may account 269 for a significant proportion of hospital-variation. Such aspects may include variability in 270 formalized structure surrounding quality improvement such as that recommended for dedicated AF Centers of Excellence.²⁰ In this context, system-level quality improvement efforts 271 may prove fruitful, primarily focusing on reducing rates of underdosing. This may be achieved 272 273 with the the development of team-based, integrated clinical care pathways developed by 274 relevant stakeholders, including pharmacy, nursing, hospital medicine, and cardiology. Key 275 components may include the establishment of pre-discharge medication review processes, 276 enhanced clinical decision support with automated dosing checks accounting for key 277 comorbidities, medications, and up-to-date laboratory values embedded in the electronic 278 medical record, and close outpatient follow-up attentive to the importance of appropriate 279 DOAC dosing. 280 Nationwide improvement in rates of recommended DOAC use and decline in the use of

281 off-label use suggest there may already be some level of recognition of the importance of 282 appropriately-dosed anticoagulation. Nonetheless, the presence of a significant, persistent gap 283 and heterogeneity in performance across hospitals underscores the need for continued, 284 focused mitigation efforts. Endeavors may include not only system-level quality improvement programs described above but also benchmarking of DOAC dosing and the development of 285 286 performance measures. Benchmarking such as that provided by quality improvement registries 287 like GWTG-AF is likely an effective feedback mechanism to stimulate improvement. In addition, 288 establishment of provider- and facility-level AF performance measures related to appropriate 289 AF dosing may also prove to be an effective a feedback mechanism and policy incentive for 290 continued quality improvement.

291 Limitations of our work include analysis of hospitals participating in the GWTG-AF 292 Registry, which may select for hospitals choosing to be involved with quality improvement 293 work. Though missing data was the major contributor to patient exclusion, the primary sample 294 size of >20,000 patients allow for meaningful analyses and represents a much greater sample in 295 comparison to other works evaluating off-label dosing. Factors considered by clinicians such as 296 frailty may influence DOAC dosing and and yet are not captured in the GWTG-AF registry. The 297 intent of our work was to evaluate rates of and factors associated with recommended and off-298 label DOAC dose in those hospitalized for atrial fibrillation, and as such whether off-label DOAC 299 dosing persisted after discharge was not evaluated. However, this study represents (1) the 300 largest work, to date, analyzing contemporary DOAC dosing and (2) the first to evaluate 301 patients hospitalized for AF and discharged on DOAC therapy.

302

303 CONCLUSIONS

304One in 10 patients hospitalized for AF are discharged on off-label doses of DOAC, with305significant variation across hospitals. Over time, rates of underdosing and overdosing declined306while the rate of recommended DOAC dosing increased. Owing to persistently elevated rates of307off-label DOAC dosing, quality-improvement efforts should be considered.

309 **REFERENCES**

311	1.	Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL,
312		Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
242		

- 313 *N Engl J Med*. 2011;365:883-891. doi: 10.1056/NEJMoa1009638
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA,
 Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial
 fibrillation. *N Engl J Med*. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR,
 Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial
- 319
 fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039
- Brokmeier H, Kido K. Off-label Use for Direct Oral Anticoagulants: Valvular Atrial
 Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis,
 Pulmonary Hypertension-a Systematic Review. Ann Pharmacother. 2021;55:995-1009.
 doi: 10.1177/1060028020970618
- 3245.Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, Xu W. Off-Label Under- and325Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-326Analysis. Circ Cardiovasc Qual Outcomes. 2021;14:e007971. doi:
- 327 10.1161/CIRCOUTCOMES.121.007971
- Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey
 KW, Naccarelli G, Reiffel J, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral
 Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. *J Am Coll Cardiol.* 2016;68:2597-2604. doi: 10.1016/j.jacc.2016.09.966
- Sugrue A, Sanborn D, Amin M, Farwati M, Sridhar H, Ahmed A, Mehta R, Siontis KC,
 Mulpuru SK, Deshmukh AJ, et al. Inappropriate Dosing of Direct Oral Anticoagulants in
 Patients with Atrial Fibrillation. *Am J Cardiol*. 2021;144:52-59. doi:
 10.1016/j.amjcard.2020.12.062
- Santos J, Antonio N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label
 doses on clinical outcomes of atrial fibrillation patients: A systematic review. *Br J Clin Pharmacol.* 2020;86:533-547. doi: 10.1111/bcp.14127
- Lewis WR, Piccini JP, Turakhia MP, Curtis AB, Fang M, Suter RE, Page RL, 2nd, Fonarow
 GC. Get With The Guidelines AFIB: novel quality improvement registry for hospitalized
 patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2014;7:770-777. doi:
 10.1161/CIRCOUTCOMES.114.001263
- 343 10. FDA Package Insert: Dabigatran.
- 344 <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf</u>.
 345 11. FDA Package Insert: Rivaroxaban.
- 346 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf.
- FDA Package Insert: Apixaban.
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
- Glorioso TJ, Grunwald GK, Ho PM, Maddox TM. Reference effect measures for
 quantifying, comparing and visualizing variation from random and fixed effects in nonnormal multilevel models, with applications to site variation in medical procedure use
 and outcomes. *BMC Med Res Methodol*. 2018;18:74. doi: 10.1186/s12874-018-0517-7

353	14.	Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin
354		use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J
355		<i>Cardiol</i> . 2011;108:1136-1140. doi: 10.1016/j.amjcard.2011.06.017
356	15.	Dawson T, DeCamillo D, Kong X, Shensky B, Kaatz S, Krol GD, Ali M, Haymart B, Froehlich
357		JB, Barnes GD. Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A
358		Population Health Approach. J Am Heart Assoc. 2020;9:e016949. doi:
359		10.1161/JAHA.120.016949
360	16.	Luo N, Xu H, Jneid H, Fonarow GC, Lopes RD, Piccini JP, Curtis AB, Russo AM, Lewis WR,
361		Matsouaka RA, et al. Use of Oral Anticoagulation in Eligible Patients Discharged With
362		Heart Failure and Atrial Fibrillation. <i>Circ Heart Fail</i> . 2018;11:e005356. doi:
363		10.1161/CIRCHEARTFAILURE.118.005356
364	17.	Rose AJ, Lee JS, Berlowitz DR, Liu W, Mitra A, Yu H. Guideline-discordant dosing of
365		direct-acting oral anticoagulants in the veterans health administration. BMC Health Serv
366		<i>Res</i> . 2021;21:1351. doi: 10.1186/s12913-021-07397-x
367	18.	Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United
368		States and United Kingdom. J Gen Intern Med. 2020;35:2505-2507. doi:
369		10.1007/s11606-020-05904-0
370	19.	Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, Hsu JC, Maddox TM. Influence
371	-	of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J Am
372		<i>Coll Cardiol</i> . 2017;69:2475-2484. doi: 10.1016/j.jacc.2017.03.540
373	20.	Piccini JP, Sr., Allred J, Bunch TJ, Deering TF, Di Biase L, Hussein AA, Lewis WR, Mittal S,
374		Natale A, Osorio J, et al. Rationale, considerations, and goals for atrial fibrillation centers
375		of excellence: A Heart Rhythm Society perspective. <i>Heart Rhythm</i> . 2020;17:1804-1832.
376		doi: 10.1016/j.hrthm.2020.04.033
377		
378		
379		
380		
381		
382		
383		
384		
385		
386		
387		
388		
389		
390		
391		
392		
393		
394		
395		
396		
-		

397 TABLES AND FIGURES

- 398
- 399 Tables
- <u>Table 1</u>: Summary of DOAC information, patient-level and hospital characteristics stratified by
 underdosed, recommended dose, overdosed and the overall cohort.
- 402
- 403 <u>Table 2</u>. Contribution to Hospital-Level Variation by Groups of Factors: All Factors, Patient-Level
 404 Factors, and Hospital-Level Factors
- 405
- 406
- 407 Figures
- 408 <u>Figure 1</u>: Rates of DOAC dosing at discharge in those hospitalized for atrial fibrillation, stratified
 409 by recommended dosing, underdosed or overdosed (percentages displayed).
- 411 Figure 2: Factors associated with off-label dosing (Panel A: Underdosing and Panel B:
- 412 Overdosing).
- 413

410

- 414 <u>Figure 3</u>: Facility-level variation in the rate of off-label DOAC use (Panel A), overdosing (Panel B)
 415 and underdosing (panel C) at discharge
- 416
 417 <u>Figure 4</u>: Trends, from 2014-2020, in the rates of recommended, under and overdosing of
 418 DOACs.
- 418 419
- 419

421 Appendix

- 422 <u>Supplemental Table 1</u>: Baseline dosing recommendation and dosing adjustments for commonly
 423 prescribed DOACs in the United States.
- 424
- 425 <u>Supplemental Figure 1</u>: Attrition plot deriving the primary cohort of interest.
- 426 427
- 428
- 429
- 430 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440

<u>Table 1</u>: Summary of DOAC information, patient-level and hospital characteristics stratified by

442 underdosed, recommended dose, overdosed and the overall cohort.

V	Overall Underdosed		Recommended	Overdosed	Devel
Variable	(N=22470)	(N=2006)	(N=19953)	(N=511)	P-value+
Demographics					
Age, Mean (years) +/- STD	70.1 +/- 12.1	76.9 +/- 11.2	69.1 +/- 11.9	80.6 +/- 7.8	<.0001
Sex, Female (%)	10818 (48.1%)	1184 (59.0%)	9295 (46.6%)	339 (66.3%)	<.0001
BMI, Mean +/- STD	31.2 +/- 7.9	29.7 +/- 7.0	31.5 +/- 7.9	25.1 +/- 5.8	<.0001
Race/Ethnicity					
White, N (%)	18530 (82.5%)	1591 (79.3%)	16516 (82.8%)	423 (82.8%)	<.0001
Black, N (%)	1398 (6.2%)	106 (5.3%)	1268 (6.4%)	24 (4.7%)	
Asian, N (%)	286 (1.3%)	35 (1.7%)	246 (1.2%)	5 (0.9%)	
Other, N (%)	739 (3.3%)	73 (3.6%)	650 (3.3%)	16 (3.1%)	
Insurance			<u>````</u>		
Missing, N (%)	216 (1.0%)	11 (0.6%)	201 (1.0%)	4 (0.8%)	<.0001
Private/HMO/Other, N (%)	9397 (41.8%)	668 (33.3%)	8584 (43.0%)	145 (28.4%)	
Medicaid, N (%)	2219 (9.9%)	198 (9.9%)	1974 (9.9%)	47 (9.2%)	
Medicare, N(%)	5260 (23.4%)	557 (27.8%)	4556 (22.8%)	147 (28.8%)	
Medicare - Private/HMO/Other, N (%)	4894 (21.8%)	544 (27.1%)	4184 (21.0%)	166 (32.5%)	
No Insurance, N (%)	484 (2.2%)	28 (1.4%)	454 (2.3%)	2 (0.4%)	
Comorbid Conditions		20 (11110)		2 (0.1.0)	
Anemia, N (%)	2095 (9.3%)	283 (14.1%)	1747 (8.8%)	65 (12.7%)	<.0001
COPD, N (%)	3698 (16.5%)	406 (20.2%)	3175 (15.9%)	117 (22.9%)	<.0001
Coronary Artery Disease, N (%)	6319 (28.1%)	703 (35.0%)	5440 (27.3%)	176 (34.4%)	<.0001
CRT-D, N (%)	307 (1.4%)	30 (1.5%)	267 (1.3%)	10 (2.0%)	0.4298
CRT-P, N(%)	57 (0.3%)	4 (0.2%)	49 (0.3%)	4 (0.8%)	0.0513
Prior Stroke or TIA, N (%)	2795 (12.4%)	320 (16.0%)	2399 (12.0%)	76 (14.9%)	<.0001
Diabetes, N (%)	6524 (29.0%)	647 (32.3%)	5750 (28.8%)	127 (24.9%)	0.0006
Dialysis, N (%)	158 (0.7%)	54 (2.7%)	92 (0.5%)	12 (2.4%)	<.0001
Heart Failure, N (%)	6570 (29.2%)	670 (33.4%)	5724 (28.7%)	176 (34.4%)	<.0001
Hypertension, N (%)	17744 (79.0%)	1663 (83.0%)	15666 (78.5%)	415 (81.2%)	<.0001
ICD Only, N (%)	723 (3.2%)	71 (3.5%)	639 (3.2%)	13 (2.5%)	0.4902
Left Ventricular Hypertrophy, N (%)	312 (1.4%)	23 (1.2%)	280 (1.4%)	9 (1.8%)	0.4946
Liver Disease, N (%)	220 (1.0%)	22 (1.1%)	193 (1.0%)	5 (1.0%)	0.8543
Mechanical Prosthetic Heart Valve, N (%)	82 (0.4%)	12 (0.6%)	68 (0.3%)	2 (0.4%)	0.1891
Mitral Stenosis, N (%)	103 (0.5%)	5 (0.3%)	95 (0.5%)	3 (0.6%)	0.3253
Obstuctive Sleep Apena, N (%)	4523 (20.1%)	265 (13.2%)	4200 (21.1%)	58 (11.4%)	<.0001
Pacemaker, N (%)	1597 (7.1%)	194 (9.7%)	1338 (6.7%)	65 (12.7%)	<.0001
Peripheral Vascular Disease, N (%)	1327 (5.9%)	163 (8.1%)	1108 (5.6%)	56 (11.0%)	<.0001
Prior Hemorrhage, N (%)	627 (2.8%)	94 (4.7%)	518 (2.6%)	15 (2.9%)	<.0001
Prior MI, N (%)	2236 (10.0%)	243 (12.1%)	1945 (9.8%)	48 (9.4%)	0.0031
Prior PCI, N (%)	2793 (12.4%)	320 (16.0%)	2394 (12.0%)	79 (15.5%)	<.0001
Rheumatic Heart Disease, N (%)	43 (0.2%)	7 (0.4%)	36 (0.2%)	0 (0%)	0.1562
Sinus Node Dysfunction, N (%)	939 (4.2%)	114 (5.7%)	786 (3.9%)	39 (7.6%)	<.0001
Smoker, N (%)	2257 (10.0%)	159 (7.9%)	2065 (10.4%)	33 (6.5%)	<.0001
Thryoid Disease, N (%)	4206 (18.3%)	487 (24.3%)	3595 (18.0%)	124 (24.3%)	<.0001

447 Table 1 (Continued)

4664 (20.8%)	465 (23.2%)	4102 (20.6%)	97 (19.0%)	< 0.000
9445 (42.0%)	832 (41.2%)	8388(42.0%)	225 (44.0%)	
5011 (22.3%)	290 (14.5%)	4629 (23.2%)	92 (18.0%)	
1217 (5.4%)	147 (7.3%)	1026 (5.1%)	44 (8.6%)	
2132 (9.5%)	272 (13.6%)	1807 (9.1%)	53 (10.4%)	
		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
785 (3.5%)	88 (4.4%)	677 (3.4%)	20 (3.9%)	<.0001
		. ,	· · · · ·	
	· · · ·	· · · · ·		
3.76 +/- 1.75	4.59 +/- 1.6	3.65 +/- 1.74	4.81 +/- 1.41	<.0001
1.93 +/- 1.53	2.74 +/- 1.47	1.82 +/- 1.5	2.90 +/- 1.39	<.0001
8456 (37.6%)	1149 (57.3%)	6950 (34.8%)	357 (69.9%)	<.000
	304 (15.2%)		. ,	<.0001
. ,	· · · /	· · · · ·	. ,	<.0001
86.39 +/- 46	61.69 +/- 35.45	90.01 +/- 46.12	42.82 +/- 16.33	<.0001
90.6 +/- 47.43	65.7 +/- 35.13	94.38 +/- 47.6	40.88 +/- 12.18	<.000
4445 (19.8%)	355 (17.7%)	3990 (20.0%)	100 (19.6%)	0.0473
18355 (81.7%)	1541 (76.8%)	16406 (82.2%)	408 (79.8%)	<.0001
. ,	. ,	. ,		
	``´´	` ´ ´		0.1204
. ,	· · · · ·	. ,	. ,	0.120
				< 0.00
. ,	. ,		. ,	<.000
· · · ·				
(/	. ,	· · · · · · · · · · · · · · · · · · ·	· · · · ·	<.000
		. ,		
	/ / X ((0 9%)	I 1691 (X 5%)	60 (11.7%)	
3143 (14.0%)	261 (13.0%)	2810 (14.1%)	72 (14.1%)	
3143 (14.0%) 4064 (18.1%)	261 (13.0%) 381 (19.0%)	2810 (14.1%) 3601 (18.1%)	72 (14.1%) 82 (16.1%)	
3143 (14.0%) 4064 (18.1%) 9497 (42.3%)	261 (13.0%) 381 (19.0%) 678 (33.8%)	2810 (14.1%) 3601 (18.1%) 8644 (43.3%)	72 (14.1%) 82 (16.1%) 175 (34.3%)	< 0.00
3143 (14.0%) 4064 (18.1%) 9497 (42.3%) 30 (0.1%)	261 (13.0%) 381 (19.0%) 678 (33.8%) 4 (0.2%)	2810 (14.1%) 3601 (18.1%) 8644 (43.3%) 26 (0.1%)	72 (14.1%) 82 (16.1%) 175 (34.3%) 0 (0%)	<.000
3143 (14.0%) 4064 (18.1%) 9497 (42.3%) 30 (0.1%) 6529 (29.1%)	261 (13.0%) 381 (19.0%) 678 (33.8%) 4 (0.2%) 423 (21.1%)	2810 (14.1%) 3601 (18.1%) 8644 (43.3%) 26 (0.1%) 5974 (29.9%)	72 (14.1%) 82 (16.1%) 175 (34.3%) 0 (0%) 132 (25.8%)	<.0001
3143 (14.0%) 4064 (18.1%) 9497 (42.3%) 30 (0.1%)	261 (13.0%) 381 (19.0%) 678 (33.8%) 4 (0.2%)	2810 (14.1%) 3601 (18.1%) 8644 (43.3%) 26 (0.1%)	72 (14.1%) 82 (16.1%) 175 (34.3%) 0 (0%)	<.000
	$\begin{array}{c} 9445\ (42.0\%)\\ 5011\ (22.3\%)\\ 1217\ (5.4\%)\\ 2132\ (9.5\%)\\ \hline\\ 785\ (3.5\%)\\ 1458\ (6.5\%)\\ 23\ (0.1\%)\\ 793\ (3.5\%)\\ \hline\\ 3.76\ +/-\ 1.75\\ 1.93\ +/-\ 1.53\\ 8456\ (37.6\%)\\ 2146\ (9.6\%)\\ 2797\ (12.5\%)\\ \hline\\ 86.39\ +/-\ 46\\ \hline\\ 90.6\ +/-\ 47.43\\ \hline\\ 4445\ (19.8\%)\\ \hline\\ 18355\ (81.7\%)\\ 984\ (4.4\%)\\ 1073\ (4.8\%)\\ \hline\\ 985\ (4.4\%)\\ 2044\ (9.1\%)\\ \hline\\ 3031\ (13.5\%)\\ \hline\\ 984\ (4.4\%)\\ 24\ (0.1\%)\\ \hline\\ 500\ (2.2\%)\\ 2289\ (10.2\%)\\ \hline\end{array}$	9445 (42.0%) 832 (41.2%) 5011 (22.3%) 290 (14.5%) 1217 (5.4%) 147 (7.3%) 2132 (9.5%) 272 (13.6%) 785 (3.5%) 88 (4.4%) 1458 (6.5%) 71 (3.52%) 23 (0.1%) 0 (0%) 793 (3.5%) 55 (2.7%) 3.76 +/- 1.75 4.59 +/- 1.6 1.93 +/- 1.53 2.74 +/- 1.47 8456 (37.6%) 1149 (57.3%) 2146 (9.6%) 304 (15.2%) 2797 (12.5%) 155 (7.7%) 86.39 +/- 46 61.69 +/- 35.45 90.6 +/- 47.43 65.7 +/- 35.13 4445 (19.8%) 355 (17.7%) 88 (4.4%) 109 (5.4%) 1073 (4.8%) 88 (4.4%) 985 (4.4%) 109 (5.4%) 2044 (9.1%) 229 (11.4%) 3031 (13.5%) 379 (18.9%) 984 (4.4%) 109 (5.4%) 24 (0.1%) 2 (0.1%) 2289 (10.2%) 318 (15.9%)	9445 (42.0%) $832 (41.2\%)$ $8388(42.0\%)$ 5011 (22.3%)290 (14.5%)4629 (23.2%)1217 (5.4%)147 (7.3%)1026 (5.1%)2132 (9.5%)272 (13.6%)1807 (9.1%)785 (3.5%)88 (4.4%)677 (3.4%)1458 (6.5%)71 (3.52%)1364 (6.8%)23 (0.1%)0 (0%)22 (0.1%)793 (3.5%)55 (2.7%)721 (3.6%)3.76 +/- 1.754.59 +/- 1.63.65 +/- 1.741.93 +/- 1.532.74 +/- 1.471.82 +/- 1.58456 (37.6%)1149 (57.3%)6950 (34.8%)2146 (9.6%)304 (15.2%)1781 (8.9%)2797 (12.5%)155 (7.7%)2590 (13.0%)86.39 +/- 4661.69 +/- 35.4590.01 +/- 46.1290.6 +/- 47.4365.7 +/- 35.1394.38 +/- 47.64445 (19.8%)355 (17.7%)3990 (20.0%)18355 (81.7%)1541 (76.8%)16406 (82.2%)984 (4.4%)109 (5.4%)841 (4.2%)2044 (9.1%)229 (11.4%)1746 (8.8%)3031 (13.5%)379 (18.9%)2541 (12.7%)984 (4.4%)109 (5.4%)841 (4.2%)2044 (9.1%)220 (0.1%)214 (1.2%)24 (0.1%)2 (0.1%)20 (0.1%)500 (2.2%)39 (1.9%)445 (2.2%)2289 (10.2%)318 (15.9%)1901 (9.5%)	9445 (42.0%) $832 (41.2%)$ $8388(42.0%)$ $225 (44.0%)$ 5011 (22.3%)290 (14.5%)4629 (23.2%)92 (18.0%)1217 (5.4%)147 (7.3%)1026 (5.1%)44 (8.6%)2132 (9.5%)272 (13.6%)1807 (9.1%)53 (10.4%)785 (3.5%)88 (4.4%)677 (3.4%)20 (3.9%)1458 (6.5%)71 (3.52%)1364 (6.8%)23 (4.5%)23 (0.1%)0 (0%)22 (0.1%)1 (0.2%)793 (3.5%)55 (2.7%)721 (3.6%)17 (3.3%)3.76 +/- 1.754.59 +/- 1.63.65 +/- 1.744.81 +/- 1.411.93 +/- 1.532.74 +/- 1.471.82 +/- 1.52.90 +/- 1.398456 (37.6%)1149 (57.3%)6950 (34.8%)357 (69.9%)2146 (9.6%)304 (15.2%)1781 (8.9%)61 (11.9%)2797 (12.5%)155 (7.7%)2590 (13.0%)52 (10.2%)86.39 +/- 4661.69 +/- 35.4590.01 +/- 46.1242.82 +/- 16.3390.6 +/- 47.4365.7 +/- 35.1394.38 +/- 47.640.88 +/- 12.184445 (19.8%)355 (17.7%)3990 (20.0%)100 (19.6%)1073 (4.8%)88 (4.4%)952 (4.8%)33 (6.5%)985 (4.4%)109 (5.4%)841 (4.2%)34 (6.7%)2044 (9.1%)229 (11.4%)1746 (8.8%)69 (13.5%)3031 (13.5%)379 (18.9%)2541 (12.7%)1111 (21.7%)984 (4.4%)109 (5.4%)841 (4.2%)34 (6.7%)2044 (9.1%)229 (11.4%)1746 (8.8%)69 (13.5%)3031 (13.5%)379 (18.9%)2541 (12.7%)11

448

449 STD = standard deviation; COPD = chronic obstructive pulmonary disease; CRT-P = cardiac

450 resynchronization therapy – pacemaker; CRT-D = cardiac resynchronization therapy –

451 defibrillator; PCI = percutaneous coronary intervention; MI = myocardial infarction; ICD =

452 implantable-cardioverter defibrillator; AF = atrial fibrillation; HMO = heatlh maintenance

453 organization

454 **Table 2**: Contribution to Hospital-Level Variation by Groups of Factors: All Factors, Patient-Level

455 Factors, and Hospital-Level Factors

456


		Reference Effect Measures* ranges and percentiles		
Outcome	Variables	Range	10 th	90 th
	All factors	[0.147, 5.496]	0.289	3.224
Underdosed	Patient factors	[0.172, 4.325]	0.328	2.826
	Hospital factors	[0.669, 2.159]	0.77	1.698
Overdosed	All factors	[0.017, 13.797]	0.082	6.606
	Patient factors	[0.017, 12.794]	0.085	6.34
	Hospital factors	[0.630, 1.187]	0.63	1.187

*Compares patients clustered within hospitals at specified percentiles of random effect distributions to similar patients in a reference, median hospital. Wider ranges indicate larger contributions to overall variation in outcome from variables.

457

458

460 **Figure 1**: Rates of DOAC dosing at discharge in those hospitalized for atrial fibrillation, stratified 461 by recommended dosing, underdosed or overdosed (percentages displayed).




OR(95% CI)

478 **Figure 2**: Factors associated with off-label dosing.

479 Panel A. Factors associated with DOAC underdosing versus recommended dosing.






480

481 Panel B. Factors associated with DOAC overdosing versus recommended dosing.


Patient and Site Characteristics		9	r.	OR(95% CI)
Patient Characteristics Age, scaled as divided by 2*SD Female vs. Male Insurance: Medicaid vs. Private/VA/Other Insurance: Medicare vs. Private/VA/Other Insurance: Medicare-Private/HMO vs. Private/VA/Other Insurance: Self pay/None vs. Private/VA/Other Weight (kg), scaled as divided by 2*SD Dialysis PVD		+ +		5.57 (4.19, 7.40) 0.79 (0.63, 0.99) 1.58 (1.10, 2.27) 1.20 (0.92, 1.56) 1.32 (1.01, 1.71) 0.32 (0.04, 2.35) 0.11 (0.08, 0.16) 5.47 (2.74, 10.88) 1.60 (1.18, 2.18)
COPD Prior Ablation Diabetes Meds Prior to Admission Antiarrhymic Prior PCI			+ + + + +	1.32 (1.05, 1.65) 1.47 (1.07, 2.02) 1.23 (0.98, 1.53) 1.23 (0.97, 1.57) 1.24 (0.96, 1.62)
Site Characteristics Region: Midwest vs. Northeast Region: South vs. Northeast Region: West vs. Northeast		+۲ ۲	4 + +	0.70 (0.44, 1.11) 1.32 (0.98, 1.78) 1.11 (0.72, 1.71)
Reference Effect Measures: 90th vs. 50th Random site variation			H	1. <mark>4</mark> 6 (1.29, 1.65)
	0.01	0.1 Odds	2 4 10	

Favors Recommended Dosing Favors Overdosing



483 Figure 3: Hospital-level variation in the rate of off-label DOAC use (panel A), overdosing (panel 484 B) and underdosing (panel C) at discharge.

Figure 4: Trends, from 2014-2020, in the rates of recommended dosing, underdosing, and 508 overdosing of DOACs.



526 Appendix

527 <u>Supplemental Figure 1</u>: Baseline dosing recommendation and dosing adjustments for

528 commonly prescribed DOACs in the United States.

	Baseline Dosing	
	Recommendation	Dosing Adjustments
		1. CrCl 30-50 ml/min = if receiving
		concomitant dronedarone, reduce to
		75mg PO BID
		2. 15-30 ml/min = 75mg PO BID unless on
	150mg PO BID for CrCl >30	dronedarone, then avoid concurrent use
Dabigatran	ml/min	3. CrCl <15 ml/min = Not Recommended
		1. 2.5mg PO BID recommended if any 2 of
		3 factors present: age <a>80 years old,
		weight <60 kg or Creatinine <a>1.5 mg/dL
		2. If on dialysis: 5mg PO BID, reduce to
		2.5mg BID if age <u>></u> 80 years or weight <u><</u> 60
Apixaban	5mg PO BID	Кg
		1. CrCl 15-50 ml/min = 15mg PO qDay
	20mg PO qDay for CrCl >50	CrCl <15 ml/min = Not Recommended
Rivaroxaban	ml/min	

552 <u>Supplemental Figure 1</u>: Attrition plot deriving the primary cohort of interest.



